Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multi-center, Open-label, Dose-escalating Phase I/II Trial of GS-9219 Administered Once Every Three Weeks Intravenously to Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin's Lymphoma or Multiple Myeloma

NCT00499239 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT00499239
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00499239 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multi-center, Open-label, Dose-escalating Phase I/II Trial of GS-9219 Administered Once Every Three Weeks Intravenously to Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin's Lymphoma or Multiple Myeloma
Lead sponsor
Gilead Sciences
Phase
Phase 1/2
Overall status
Terminated
Start date
July 31, 2007
Completion date
October 31, 2010
Enrollment
32 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia, multiple myeloma, non-hodgkin's lymphoma